Roche’s Kadcyla gets FDA nod for adjuvant treatment of HER2+ early breast cancer

This article was originally published here

The latest approval for Kadcyla is for HER2-positive early breast cancer patients with residual invasive disease after being subjected to neoadjuvant treatment with taxane and Herceptin (trastuzumab). The

The post Roche’s Kadcyla gets FDA nod for adjuvant treatment of HER2+ early breast cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply